Last reviewed · How we verify
arformoterol (RR formoterol)
Arformoterol is a long-acting beta-2 adrenergic agonist that binds to beta-2 receptors on airway smooth muscle to cause bronchodilation and improve airflow.
Arformoterol is a long-acting beta-2 adrenergic agonist that binds to beta-2 receptors on airway smooth muscle to cause bronchodilation and improve airflow. Used for Chronic obstructive pulmonary disease (COPD), Asthma (maintenance therapy).
At a glance
| Generic name | arformoterol (RR formoterol) |
|---|---|
| Also known as | Brovana |
| Sponsor | Henry Ford Health System |
| Drug class | Long-acting beta-2 adrenergic agonist (LABA) |
| Target | Beta-2 adrenergic receptor (ADRB2) |
| Modality | Small molecule |
| Therapeutic area | Respiratory |
| Phase | FDA-approved |
Mechanism of action
Arformoterol is the active R,R-enantiomer of formoterol, a selective beta-2 adrenergic receptor agonist. Upon binding to beta-2 receptors on bronchial smooth muscle, it activates adenylyl cyclase via G-protein coupling, increasing intracellular cAMP levels and leading to smooth muscle relaxation and sustained bronchodilation. As a long-acting formulation, it provides extended therapeutic effect over 12-24 hours.
Approved indications
- Chronic obstructive pulmonary disease (COPD)
- Asthma (maintenance therapy)
Common side effects
- Tremor
- Headache
- Palpitations
- Muscle cramps
- Nervousness
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- arformoterol (RR formoterol) CI brief — competitive landscape report
- arformoterol (RR formoterol) updates RSS · CI watch RSS
- Henry Ford Health System portfolio CI